{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:21:56Z","timestamp":1761942116950,"version":"build-2065373602"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.jbo.2018.09.010","type":"journal-article","created":{"date-parts":[[2018,10,2]],"date-time":"2018-10-02T18:51:24Z","timestamp":1538506284000},"page":"100199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5228-6387","authenticated-orcid":false,"given":"Peyman","family":"Hadji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Stoetzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Decker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian M.","family":"Kurbacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6591-3367","authenticated-orcid":false,"given":"Frederik","family":"Marm\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Schneeweiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Mundhenke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Distelrath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A.","family":"Fasching","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"Lux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"L\u00fcftner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Janni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias","family":"Muth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Kreuzeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Quiering","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva-Marie","family":"Grischke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7839-4917","authenticated-orcid":false,"given":"Hans","family":"Tesch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 7","key":"10.1016\/j.jbo.2018.09.010_bib0001","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2009.0080","article-title":"The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors","volume":"7","author":"Lipton","year":"2009","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"Suppl 3","key":"10.1016\/j.jbo.2018.09.010_bib0002","doi-asserted-by":"crossref","first-page":"iii124","DOI":"10.1093\/annonc\/mdu103","article-title":"Bone health in cancer patients: ESMO clinical practice guidelines","volume":"25","author":"Coleman","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbo.2018.09.010_bib0003","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s11914-013-0179-7","article-title":"Skeletal manifestations of treatment of breast cancer","volume":"11","author":"Choksi","year":"2013","journal-title":"Curr. Osteoporos. Rep."},{"key":"10.1016\/j.jbo.2018.09.010_bib0004","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1007\/s12325-013-0060-1","article-title":"Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis","volume":"30","author":"Yardley","year":"2013","journal-title":"Adv. Ther."},{"key":"10.1016\/j.jbo.2018.09.010_bib0005","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2018.09.010_bib0006","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/jnci\/djt026","article-title":"Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2","volume":"105","author":"Gnant","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jbo.2018.09.010_bib0007","article-title":"Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: results of the single-arm phase IIIB 4EVER trial","author":"Tesch","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jbo.2018.09.010_bib0008","unstructured":"Mayo Clinic, Mayo Medical Laboratories. Test catalog. http:\/\/www.mayomedicallaboratories.com\/test-catalog\/index.html. Accessed 21 May 2018."},{"key":"10.1016\/j.jbo.2018.09.010_bib0009","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00432-010-0964-y","article-title":"The effect of exemestane and tamoxifen on bone health within the tamoxifen exemestane adjuvant multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies","volume":"137","author":"Hadji","year":"2011","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.jbo.2018.09.010_bib0010","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1470-2045(07)70003-7","article-title":"Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study","volume":"8","author":"Coleman","year":"2007","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jbo.2018.09.010_bib0011","article-title":"Effect of neoadjuvant chemotherapy on the serum levels of bone turnover markers in women with early-stage breast cancer","volume":"10","author":"Chen","year":"2015","journal-title":"PLoS One"},{"issue":"Suppl 4","key":"10.1016\/j.jbo.2018.09.010_bib0012","article-title":"Changes of bone turnover markers during perioperative anthracycline- and\/or taxane-based chemotherapy in pre- and postmenopausal patients with primary breast cancer","volume":"76","author":"Kurbacher","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbo.2018.09.010_bib0013","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13058-017-0885-7","article-title":"Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer","volume":"19","author":"Browne","year":"2017","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.jbo.2018.09.010_bib0014","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/sj.cdd.4401285","article-title":"M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR\/S6 kinase","volume":"10","author":"Glantschnig","year":"2003","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.jbo.2018.09.010_bib0015","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.bbrc.2009.04.084","article-title":"Down-regulation of mTOR leads to up-regulation of osteoprotegerin in bone marrow cells","volume":"384","author":"Mogi","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jbo.2018.09.010_bib0016","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.critrevonc.2013.05.015","article-title":"Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus","volume":"87","author":"Hadji","year":"2013","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.jbo.2018.09.010_bib0017","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.bone.2004.07.013","article-title":"Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts","volume":"35","author":"Kneissel","year":"2004","journal-title":"Bone"}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137418301131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137418301131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:17:01Z","timestamp":1761941821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137418301131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":17,"alternative-id":["S2212137418301131"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2018.09.010","relation":{},"ISSN":["2212-1374"],"issn-type":[{"type":"print","value":"2212-1374"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2018.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100199"}}